Research programme: theranostics - Clarity Pharmaceuticals

Drug Profile

Research programme: theranostics - Clarity Pharmaceuticals

Alternative Names: SAR-Discovery; SAR-PSMA; SAR-PSMA PET imaging - Clarity Pharmaceuticals; SAR-PSMA therapy - Clarity Pharmaceuticals

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Antineoplastics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma; Ovarian cancer; Prostate cancer

Most Recent Events

  • 26 Sep 2017 Preclinical trials in Glioma (Diagnosis) in Australia (Parenteral) before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
  • 26 Sep 2017 Preclinical trials in Glioma in Australia (Parenteral) before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
  • 26 Sep 2017 Preclinical trials in Ovarian cancer (Diagnosis) in Australia (Parenteral) before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top